Why IO Biotech Filed For Bankruptcy

Biotech just delivered another brutal reminder: one regulatory decision can erase years of work overnight. IO Biotech didn’t just stumble—they folded entirely after the FDA shut the door on their lead cancer therapy.

The “Need-to-Know”

Breakdown:

The FDA Blow:

IO Biotech’s lead immunotherapy failed to clear a critical FDA hurdle, effectively killing its path to market. Without approval, the company’s core asset lost most of its value instantly. 

The Cash Crunch:

Biotech firms live and die on funding timelines. Once the FDA rejection hit, raising new capital became nearly impossible. Investors don’t fund uncertainty—they exit it.

The Surrender:

Rather than drag out restructuring or attempt a risky pivot, IO Biotech filed for bankruptcy, signaling there was no viable backup plan strong enough to justify survival.

The Pipeline Problem:

This wasn’t just about one drug. The company’s broader pipeline wasn’t mature enough to step in and replace the failed therapy, leaving them exposed to a single-point failure.

The Industry Pattern:

This is becoming a recurring theme in biotech:

•	Heavy reliance on one flagship drug

•	Binary FDA outcomes

•	Immediate valuation collapse on rejection

The Bigger Signal:

The FDA isn’t loosening standards, and capital markets aren’t forgiving misses. That combination is creating a much harsher environment for smaller biotech firms trying to survive long enough to commercialize.

⸻

So what does this actually mean?

Are biotech companies becoming too dependent on single “all-or-nothing” drugs?

Is the FDA tightening standards, or are companies overpromising early-stage science?

And how many more small biotech firms are one failed decision away from the same outcome?